Negara: Kanada
Bahasa: Inggris
Sumber: Health Canada
ACEBUTOLOL HYDROCHLORIDE
SANOFI-AVENTIS CANADA INC
C07AB04
ACEBUTOLOL
200MG
TABLET
ACEBUTOLOL HYDROCHLORIDE 200MG
ORAL
100/500
Prescription
BETA-ADRENERGIC BLOCKING AGENTS
Active ingredient group (AIG) number: 0112995003; AHFS:
CANCELLED POST MARKET
2010-10-26
_ _ _ _ _Page 1 of 33_ PRODUCT MONOGRAPH PR RHOTRAL ® (acebutolol hydrochloride) _ _ _ _ _ _ 100, 200, and 400 mg Tablets Antiyhypertensive and Anti-anginal Agent ATC Code: C07AB04 sanofi-aventis Canada Inc. 2150 St. Elzear Blvd. West Laval, Quebec H7L 4A8 Date of Revision: January 14, 2009 Submission Control No.: 125506 s-a Version dated _ _ _ _ _Page 2 of 33_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION......................................................... 3 SUMMARY PRODUCT INFORMATION................................................................................ 3 INDICATIONS AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS .......................................................................................................... 4 WARNINGS AND PRECAUTIONS ......................................................................................... 4 ADVERSE REACTIONS........................................................................................................... 9 DRUG INTERACTIONS ......................................................................................................... 12 DOSAGE AND ADMINISTRATION ..................................................................................... 15 OVERDOSAGE ....................................................................................................................... 16 ACTION AND CLINICAL PHARMACOLOGY.................................................................... 17 STORAGE AND STABILITY ................................................................................................. 19 DOSAGE FORMS, COMPOSITION AND PACKAGING ..................................................... 19 PART II: SCIENTIFIC INFORMATION ............................................................................... 20 PHARMACEUTICAL INFORMATION................................................................................. 20 DETAILED PHARMACOLOGY .................... Baca dokumen lengkapnya